QCDx specializes in the detection and characterization of circulating tumor cells (CTCs) and develops proprietary liquid biopsy technologies for enrichment-free detection and proteomic profiling of CTCs. The company delivers its capabilities through advanced medical instrumentation and CLIA-certified laboratory services. QCDx plans to launch a new diagnostic instrument, a breast cancer monitoring assay, proprietary multiplex immunofluorescence reagent kits, and a CLIA-certified clinical laboratory. It intends to complete a breast cancer clinical validation study in partnership with UCONN Health and relocate to its new CLIA-certified laboratory facility this year. The company closed a $7M financing comprised of $5.3M in intermediate-term debt under a credit facility and the conversion of $1.7M in existing convertible notes into equity. Sagittarius Advisors LLC served as the administrative agent for the facility.

Total raised

$2M

Funding rounds

1

Latest round

Equity

Latest activity

May 2025